News

New AI-powered add-on for T-cell therapy candidate detection—in collaboration with ImmunoMind

eLabNext launches a new AI (Artificial Intelligence) powered add-on developed by ImmunoMind. This collaboration allows eLabNext users to leverage their existing data as input in the ImmunoMind platform.

A laboratory

Download Whitepaper

By submitting this form, you agree with our Privacy Policy.
Thank you! Download the file by clicking below:
Download
Oops! Something went wrong while submitting the form.

Table of Contents

Publish Date

Author

Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.

Table of Contents

eLabNext launches a new AI (Artificial Intelligence) powered add-on developed by ImmunoMind. This collaboration allows eLabNext users to leverage their existing data as input in the ImmunoMind platform. This data helps guide users through translational and clinical research to help better understand T-cell therapies using computation immunology and AI technologies which enhances the reports from eLabJournal with the results from multi-omics driven drug development and manufacturing.

ImmunoMind is a moonshot startup—graduated from UC Berkeley SkyDeck—that helps companies and medical centres select safer and more effective CAR-T and other Cell Therapies. By using proprietary multi-omics and AI technologies, their platform allows early and comprehensive assessment of potential candidates.

How it works

The ImmunoMind add-on precisely identifies both cell subpopulations (e.g. Tscm, Tcm, Tem, Treg, NK, gdT cells) and their characteristics (e.g. exhaustion, senescence, activation) to create a comprehensive profile of CAR-T and other Cell Therapy products. The profile can help select the most effective design and dosage for CAR-T, improve QC and SOP to select T-cell subsets (such as Tscm and T-cell precursors), assess exhaustion and persistence of CAR-T cells in vitro and in vivo, and more. The platform supports Go/No-Go decision-making and reduces the risk of immunotherapy development and manufacturing.

Collaboration at its best

eLabNext values efficient and secure collaboration within the lab and across departments. We provide digital solutions to align all diverse teams within an organization. With this integration, you will be able to bring forward the synergy between biologists, medical scientists, data scientists and bioinformaticians. We value the resources it takes to follow through with all the stages of drug development and manufacturing—which is precisely why we put our efforts into providing everyone with an automated and streamlined process.

The ImmunoMind add-on is free and available in eLab Marketplace

Install the free ImmunoMind add-on to connect eLabJournal with the ImmunoMind platform for more enriched reporting.

Not yet using eLab? Try the add-on free for 30 days in a free trial. Sign up now!

eLabNext launches a new AI (Artificial Intelligence) powered add-on developed by ImmunoMind. This collaboration allows eLabNext users to leverage their existing data as input in the ImmunoMind platform. This data helps guide users through translational and clinical research to help better understand T-cell therapies using computation immunology and AI technologies which enhances the reports from eLabJournal with the results from multi-omics driven drug development and manufacturing.

ImmunoMind is a moonshot startup—graduated from UC Berkeley SkyDeck—that helps companies and medical centres select safer and more effective CAR-T and other Cell Therapies. By using proprietary multi-omics and AI technologies, their platform allows early and comprehensive assessment of potential candidates.

How it works

The ImmunoMind add-on precisely identifies both cell subpopulations (e.g. Tscm, Tcm, Tem, Treg, NK, gdT cells) and their characteristics (e.g. exhaustion, senescence, activation) to create a comprehensive profile of CAR-T and other Cell Therapy products. The profile can help select the most effective design and dosage for CAR-T, improve QC and SOP to select T-cell subsets (such as Tscm and T-cell precursors), assess exhaustion and persistence of CAR-T cells in vitro and in vivo, and more. The platform supports Go/No-Go decision-making and reduces the risk of immunotherapy development and manufacturing.

Collaboration at its best

eLabNext values efficient and secure collaboration within the lab and across departments. We provide digital solutions to align all diverse teams within an organization. With this integration, you will be able to bring forward the synergy between biologists, medical scientists, data scientists and bioinformaticians. We value the resources it takes to follow through with all the stages of drug development and manufacturing—which is precisely why we put our efforts into providing everyone with an automated and streamlined process.

The ImmunoMind add-on is free and available in eLab Marketplace

Install the free ImmunoMind add-on to connect eLabJournal with the ImmunoMind platform for more enriched reporting.

Not yet using eLab? Try the add-on free for 30 days in a free trial. Sign up now!

Ready to transform your lab?

Enhance lab operations, improve collaboration, and ensure data security with eLabNext.

Check icon

Experiment management

Check icon

Inventory management

Check icon

Improved collaboration

Check icon

Protocol management

Check icon

Research workflow management

A scientist woman

Sign up for our newsletter

Get the latest tips, articles, and exclusive content on modern lab management delivered to your inbox.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.